For excellence in diagnostics
– We’re bound to deliver

Medix Biochemica is a Finnish biotechnology company that develops, produces and markets monoclonal antibodies, antibody services and recombinant antigens for IVD industry as well as diagnostic rapid tests for human healthcare worldwide.

Business Activities

MedixMAB™ Antibodies & MedixAntigens

When we started the industrial-scale manufacturing of monoclonal antibodies over 30 years ago, we created a new paradigm for the antibody industry. Now our product range covers monoclonal antibodies, fab fragments and recombinant antigens for a variety of markers.

Learn more

MedixMAB™ Contract Manufacturing

We offer a highly cost-effective service for in vitro monoclonal antibody and recombinant antigen production. Our customised turnkey contract manufacturing service makes antibody and antigen production both effortless and worry-free, with our fully certified quality control system.

Learn more

Actim® Rapid Tests

Actim® Rapid Tests give results within minutes. They are specifically developed for use at point-of-care and in medical emergencies when quick and accurate diagnosis can make all the difference.

Learn more

Our core competencies are
at the heart of everything we do

  • Flexible production – from milligrams to hundreds of grams
  • Constant quality – from batch to batch
  • Quick and accurate deliveries globally
  • Competitive pricing

Standing behind the quality

  • We are committed to high quality in all our activities
  • We develop reliable diagnostic products which are safe, effective and suitable for their intended use and their performance is scientifically justified
  • Our products and operations meet the needs and expectations of our customers
  • We comply with the relevant regulatory requirements
  • Profitability of our operations meets the expectations of our owners

Quality management system

  • ISO 13485
  • EN ISO 13485 certificate
  • QSR, 21CFR820

Company Milestones

Medix Biochemica is owned by the Minerva Foundation, a medical research foundation which was established by senior medical scientists in 1959. Medix Biochemica is proud to say that we are one of the first companies in the world to produce monoclonal antibodies, starting only three years after Köhler and Milstein published their Nobel Prize winning work on the subject. Medix Biochemica was established in 1985 to meet the growing demand for developing and producing monoclonal antibodies.

1959 Minerva Foundation founded
1964 Medix Ltd. founded
1970 Reagent manufacturing established
1979 Manufacturing of monoclonal antibodies established
1985 Medix Biochemica founded
1990 Rapid test manufacturing established in Joensuu factory
1994 First Actim tests released
2003 ISO 13485 compliance
2006 FDA QSR compliance
2015 New facilities in Espoo
2016 Medix China established


Career with us!

Medix Biochemica employs ca. 100 highly trained professionals. Review the open positions and apply online.

If you are interested in becoming one of us, please click the following link to see our open vacancies: Open positions and applications and apply for positions online. If there are not any vacancies that suit your interest, you can send us an open application.

Contact Information

Contact Us

Please don’t hesitate to contact us – we look forward to hearing from you!

Get in contact